BACKGROUND: Sigma ()-receptor agonists attenuate brain injury after experimental focal cerebral ischemia in several species. We tested the hypothesis that the potent, prototypical 1 -receptor agonist, 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP), protects neurons by a mechanism involving the antiapoptotic protein bcl-2. METHODS: Primary cortical neuronal cultures were exposed to either 2 h of oxygen-glucose deprivation (OGD) or glutamate (100 M). PPBP treatment was initiated either 15 min prior to the insult or at 15 min postinsult then continued for 24 h. In another set of experiments, cultured neurons were preincubated for 2 h prior to PPBP treatment with 1 -receptor antagonist, rimcazole, in a dosedependent manner. Alive and dead cells were detected with calcein-AM and propidium iodide respectively. Bcl-2 and bax expression were determined by quantitative real time reverse transcription polymerase chain reaction and western blotting, and DNA damage was detected by TUNEL staining. RESULTS: PPBP pretreatment attenuated neuronal injury induced by OGD or glutamate (50 or 100 M). This protection was reversed with rimcazole (cell death: OGD 48 Ϯ 2%, OGD plus PPBP 31 Ϯ 3%, OGD plus PPBP with rimcazole 46 Ϯ 2%). PPBP treatment increased bcl-2 but not bax mRNA levels. PPBP's ability to preserve bcl-2 protein after OGD by PPBP was fully abolished by rimcazole. Lastly, PPBP reduced the number of TUNEL-positive cells after OGD, suggesting fewer cells with overt DNA damage.
tective in animal models of cerebral ischemia (1) (2) (3) (4) (5) . We (1) (2) (3) (4) (5) have previously demonstrated that the potent and prototypic sigma 1 ( 1 ) receptor agonist, 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP), attenuates stroke volume after focal cerebral ischemia in three animal species (cat, rat, and mouse). Sigma receptor ligands interact with numerous neurotransmitter systems in the brain (6) and may have potent antiexcitotoxic properties. While some studies suggest a presynaptic mechanism involving inhibition of ischemia-induced presynaptic glutamate release (7), others suggest receptor-mediated or postsynaptic mechanisms such as inhibition of dopaminergic neurotransmission (8) , prevention of cortical spreading depression (9) , modulation of neuronal responses to N-methyl-d-aspartate (NMDA) receptor stimulation (10) , attenuation of postsynaptic glutamate-evoked Ca 2ϩ influx (11) , attenuation of glutamate-and NMDA-induced nitric oxide (NO) synthase activation (10) , and attenuation of ischemia-evoked NO production (5) . Accordingly, we tested the hypothesis that PPBP protects neurons in vitro by a mechanism specific to the 1 receptor and to modulation of antiapoptotic bcl-2 by determining neuronal viability after exposure of primary neuronal cultures to PPBP and the selective 1 -receptor antagonist, rimcazole as well as assessed DNA fragmentation, bcl-2 and bax mRNA with quantitative polymerase chain reaction (PCR) and immunoblotting techniques.
METHODS
Experimental protocols were approved by the Institutional Animal Care and Use Committee and conform to the National Institutes of Health guidelines for the care and use of animals in research.
from Sigma (St. Louis, MO), and calcein AM from Molecular Probes (Eugene, OR). The antibody against bcl-2 was obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Primary Neuronal Cell Cultures
Primary cortical neuronal cultures were established from E18 Sprague-Dawley rat pups (Charles River, MA), as described previously (12) ) in minimum essential medium supplemented with 10% horse serum, 2 mmol/L l-glutamine, 50 U/50 g/mL penicillin-streptomycin, and 25 mM glucose. Cells were kept for 30 min in minimum essential medium, which was subsequently replaced with cultivating medium (Neurobasal medium supplemented with 2% B27 and 2.0 mM Glutamax) and grown at 37°C in 100% humidity, 95% room air/5% CO 2 . All experiments were performed at 11-12 DIV and 37°C.
For oxygen-glucose deprivation (OGD) experiments, media was replaced with buffer (phosphate buffered saline with 1 mM CaCl 2 , 0.8 mM MgCl 2 , previously saturated with 95% N 2 /5% CO 2 for 10 min) and then placed in a hypoxic environment incubator for 2 h (Thermo Forma 3130, OH; 94% N 2 , 1% O 2 , and 5% CO 2 ). For reoxygenation, cells were again placed into the cultivating medium and returned to normoxic conditions. Control cells were washed with OGD buffer and maintained in media. In drug treatment studies, cells were pretreated with PPBP in OGD buffer for 15 min prior to OGD. For postinjury treatment, PPBP (10 M) was added 15 min and 1 h after completion of OGD. To assess the role of the 1 -receptor, the selective receptor antagonist rimcazole (1 or 5 M) was added to the culture medium (13) . Rimcazole was applied for 2 h, followed by PPBP for 30 min, and then cells were exposed to 2 h OGD at 37°C and 24 h of recovery. To assess excitotoxicity, cultures were exposed to 24 h of glutamate (100 M). Cells were either pretreated with PPBP (10 M, administered 15 min prior to glutamate exposure) or posttreated (administered at 15 min of glutamate exposure).
Assessment of Neuronal Viability
Cell viability was assessed by PI and Calcein-AM uptake (14) using the Nikon inverted microscope (Nikon Eclipse TE200). Cultured neurons were incubated with 1 g/mL calcein-AM for 30 min; 10 g/mL PI was then added for 15 min in medium at 37°C. For cell counting, cells were visualized using a Nikon 40ϫ objective lens (Nikon DXM1200). In a blinded fashion, three images per well (24 wells) were generated and three wells for each condition were analyzed. Cell mortality is expressed as the ratio of PI-positive cells/calcein positive ϩ PI positive cells.
DNA Fragmentation
Cells were fixed in 10% formalin and then washed in phosphate-buffered saline. The fluorescein-based terminal, deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) technique (Roche Molecular Biochemicals, IN) was used to label doublestranded DNA breaks as described previously (15) . Cells were then counterstained with 4Ј,6-dimidino-2-phenylindole (DAPI) to assess nuclear morphology. The number of TUNEL and DAPI stained cells were counted in OGD-and OGD with PPBP-treated cultures, then averaged over three separate experiments and are expressed as the ratio of TUNEL positive to DAPI stained cells.
Determination of bcl-2 and bax mRNA with Quantitative PCR (qPCR)
Total RNA was isolated (Promega total RNA system, Madison, WI) using the manufacturer's protocol. cDNA was reverse transcribed from 2.5 g total RNA in 50 L RT reaction mix at 37°C for 2 h using random hexamers as primers (High-Capacity cDNA Archive Kit; Applied Biosystems, Foster City, CA); cDNA (50 ng) was used for qPCR. Primers and Taqman probes for rat bcl-2 and bax were designed from known sequences for rat bcl-2 mRNA (NM016993) and bax (AF235993) according to the recommended criteria using Primer Express (Version 2.0, Applied Biosystem). For bcl-2, the sequences were 5Ј-TGG GAT GCC TTT GTG GAA CTA T-3Ј (forward primer), 5Ј-AGA GAC AGC CAG GAG AAA TCA AAC-3Ј (reverse primer) and 5Ј-FAM-TGG CCC CAG CAT GCG ACC TC-TAMRA (Probe), and the amplicon spanned from 808 to 875 bp. For bax, the sequences were: 5Ј-GGG TGG TTG CCC TTT TCT ACT-3Ј (forward primer), 5Ј-CCC GGA GGA AGT CCA GTG TC-3Ј (reverse primer) and 5Ј-FAM-ACT GGT GCT CAA GGC CCT GTG CA-TAMRA (Probe), and the amplicon spanned from 780 to 890 bp. qPCR was performed in ABI Prism 7000 DNA Detection System with probe and primer concentrations of 250 and 300 nM, respectively, in the final PCR reaction mix. Cycling variables were: 2 min at 50°C, 10 min at 95°C and then 40 cycles of 15 s at 95°C and 1 min at 60°C. Controls were performed under the same conditions, including No RNA template control and reverse transcription-negative control bax PCR primers and probe were validated using RNA isolated from thymus as positive control. Data were normalized to 18S RNA for each sample (18S Genomic Endogenous Control Kit; Eurogentec, North America, San Diego, CA) and expressed as a percentage of control values.
Immunoblotting
Western blotting was performed as described previously (16), with modifications. Cell culture extracts were lysed in buffer (50 mM Tris-HCl (pH 7.5), 0.1% SDS, 1% NP-40, 150 mM NaCl, 0.04% deoxycholic acid sodium salt, 5 mM EDTA, 50 mM NaF with protease inhibitors. Protein concentration was determined with a BCA kit (Pierce, Rockford, IL), separating 30 g of protein on 12% SDS-PAGE then transferred to nitrocellulose membrane. Anti-bcl-2 antibody was diluted 1:1000, anti-␤-actin 1:3000 and incubated at room temperature for 2 h. Membranes were incubated with anti-mouse IgG conjugated to horseradish peroxidase (Jackson Immunoresearch, Plymouth, PA) for 1 h. Protein bands were visualized with ECL (Amersham Biosciences, Buckinghamshire, England), and optical density was quantified (MCID Imaging Research).
Statistical Analysis
All results are presented as mean Ϯ sem. Statistical significance was determined by one-way ANOVA (SigmaStat 3.0), with post hoc correction using the Tukey multiple comparison test. For western blot optical densitometry, a Student-Newman-Keuls test was used. Student's t-test was used for variables in which only a single comparison was necessary. A value of P Ͻ 0.05 was considered statistically significant.
RESULTS

Effect of PPBP on Glutamate or OGD-Induced Cell Death
PPBP treatment did not result in detectable cell death at concentrations of 5, 10, or 20 M when applied for 24 h of normoxic conditions. However, high concentrations of PPBP (100 M) for 24 h resulted in significant cell death (78.5% versus untreated cells) (data not shown). Glutamate exposure (10 -100 M) resulted in dose-dependent cell death that was ameliorated by 10 M PPBP (Fig. 1) . PPBP pretreatment completely prevented glutamate-induced cell death, while PPBP applied 15 min into glutamate exposure was ineffective (glutamate: 40 Ϯ 1%, glutamate ϩ PPBP: 37 Ϯ 1%; n ϭ 3). Two hours of OGD resulted in significant cell death as assessed 24 h postinjury. Pre-OGD treatment with PPBP (5, 10, or 20 M) significantly attenuated neuronal injury ( Fig. 2A) . PPBP 10 M post-ODG treatment, whether early (at 15 min of reoxygenation) or delayed (1 h of reoxygenation), also attenuated OGD-induced cell death (Fig.  2B) . Preincubation with the 1 -receptor antagonist, rimcazole (1 or 5 M) blocked the protective effect of PPBP treatment (Fig. 3) .
Modulation of Postinjury bcl-2 Gene Expression and TUNEL Positive Cells by PPBP
Under controlled conditions, Western blot analysis did not demonstrate any effect of PPBP alone on bcl-2 protein expression (Fig. 4) . To further characterize the effects of PPBP after OGD and glutamate-induced neuronal cell death, we used qPCR analysis of bcl-2 and bax mRNA. Cells were treated in two ways: (1) 2 h OGD then recovered for 3 h with or without pretreatment with 10 M PPBP or (2) 100 M glutamate for 3 h with or without PPBP. PPBP treatment enhanced bcl-2 mRNA expression after glutamate (3 h) or OGD (3 h). Figures 5A and B depicts bcl-2 mRNA levels after normalization to 18SRNA, then expressed as a percentage of control values. In contrast, there were no changes observed in bax gene expression with PPBP in either condition. In companion experiments, pretreatment with PPBP blunted loss of bcl-2 protein in OGD (2 h followed by 6 h recovery) (Fig. 6) . PPBP-induced bcl-2 preservation was abolished by treatment with rimcazole ( Fig. 7) . Lastly, PPBP reduced TUNELpositive cells (Fig. 8) after OGD, suggesting fewer cells with overt DNA damage, (TUNEL-positive/DAPI stained cells after 2 h OGD and 24 h recovery: OGD 26 Ϯ 2%, OGD with PPBP 11 Ϯ 2% P Ͻ 0.05).
DISCUSSION
This study demonstrates two important and novel findings. First, the 1 -receptor agonist PPBP strongly attenuates neuronal injury in vitro after OGD or excitotoxic insult. Protection is specific to the 1 -receptor, as the selective antagonist rimcazole reverses PPBP's beneficial action. Second, PPBP enhances antiapoptotic bcl-2 mRNA levels and preserves bcl-2 protein load, an effect reversed by the inhibitor rimcazole. The effect was specific, in that no effect was observed in expression of proapoptotic bax. These data suggest that neuroprotection with PPBP is mediated by mechanism(s) involving bcl-2 transcription and preservation of a favorable bcl-2/bax ratio in injured neurons.
First described almost three decades ago, -receptors are unique binding sites for selected endogenous and pharmacological ligands (17) . The 1 -receptor has been cloned from human (18) , mouse (19) and rat brain (20) has widespread labeling (21) , and interacts with several excitatory neurotransmitter systems. We and others have repeatedly demonstrated ischemic neuroprotection in vivo, using well characterized rodent and nonrodent models of focal cerebral ischemia (1) (2) (3) (4) (5) . The present findings extend these in vivo observations to characterize PPBP's ability to block cell death after excitotoxic killing and energy failure in vitro.
Our previous work (1-3) strongly supports the potential for 1 -agonists as neuroprotective agents in ischemic stroke based on the observations that PPBP provides robust ischemic neuroprotection in three animal models (mouse, rat, and cat) of cerebral ischemia. Ischemic neuroprotection with NMDA receptor antagonists has long been the focus of human stroke Figure 5 . A. Increased bcl-2 mRNA as measured by qPCR in cortical neurons pretreated with PPBP10 M then exposed to glutamate. bcl-2 mRNA was normalized to 18S RNA and expressed as the percentage of control (n ϭ 6). *P Ͻ 0.05 versus glutamate exposure. B. Increased bcl-2 mRNA as measured by qPCR in cortical neurons pretreated with 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) 10 M then exposed to oxygen-glucose deprivation (OGD) (2 h) with 3 h recovery. bcl-2 mRNA was normalized to 18S RNA and expressed as the percentage of control (n ϭ 5). *P Ͻ 0.05 versus OGD. clinical trials because of their robust neuroprotective effects in animal models. The limitation of these drugs has been their phencyclidine-like central nervous system effects, including hallucinations, agitation, confusion, and delirium. In our experimental work in the rat model of focal ischemia, although middle cerebral artery occlusion was associated with several alterations in behavior, treatment with PPBP had no effect on behavioral outcomes (1) over a 7-day observation period. In a previous study, histopathologic evaluation showed no evidence of neuronal dropout or morphologic changes between PPBP and vehicletreated rats (22) . Specifically, there were no morphologic changes observed in the cingulate gyrus and the retrosplenial cerebral cortex typically seen with NMDA toxicity (23) .
In part, mechanisms that account for these neuroprotective properties may be linked to the concept that 1 -receptors modulate NMDA receptor activation (24) . Previous studies indicate that -receptor stimulation inhibits ischemia-induced, presynaptic glutamate release (7). However, 1 /NMDA receptor interactions may be dependent on the physiologic response being studied, and on the brain region involved. Postsynaptic, receptormediated mechanism(s) have also been described, including inhibition of dopaminergic neurotransmission (8) , attenuation of glutamate and NMDA induced (10) , and ischemia-evoked NO production (5) and attenuation of postsynaptic glutamate-evoked Ca 2ϩ influx (11) . The present findings with rimcazole suggest that PPBP's protection in cortical neurons is transduced by the 1 receptor. Two known sub-types have been identified, 1 and 2 , based on regional distribution, enantomeric selectivity, molecular weights, and downstream signaling partners (10) . In the present study, we used PPBP as a prototypical 1 -receptor agonist with high subtype selectivity. The 1 -receptor agonist, (ϩ) pentazocine, has likewise been shown to be effective in focal cerebral ischemia (25) . However, the selectivity of many -receptor agonists are concentration-dependent. While both PPBP and (ϩ) pentazocine are considered selective 1 -receptor agonists (21), (ϩ) pentazocine, at high concentrations, inhibits the NMDA-receptor phencyclidine site (26) . We have previously demonstrated that PPBP enhanced NO production in vivo is completely attenuated by the 1 -receptor antagonist 1-(cyclopropylmethyl)-4-(2Ј-oxoethyl) piperidine hydrobromide (DuP 734) indicating that the effects of PPBP are mediated via the 1 -receptor. The specific affinity of PPBP for 1 -receptor is not known. The IC 50 and Ki for rimcazole for the binding sites for (ϩ)-3-PPP [(3-hydroxyphenyl)-N-(1-propyl) piperidine)] is in the 1-2 M range (13) . Therefore, we sought in the present study to verify that PPBP attenuates neuronal injury in a dose-dependent fashion and that its actions are secondary to its direct interaction with the 1 -receptor.
We observed early in our study that PPBP attenuated the appearance of TUNEL-positive cells after OGD, and hypothesized that the agonist could be altering delayed cell death by elaborating prosurvival bcl-2 or by suppressing bax. Although our data do not address transcriptional mechanisms by which postinjury bcl-2 expression is enhanced by PPBP, the study is the first to demonstrate an interaction of 1 -receptor agonist with antiapoptotic gene expression. It is important to note that bax mRNA was completely unaltered by PPBP, while changes in bcl-2 were readily evident. Therefore, it seems unlikely that changes in bcl-2 transcripts or protein load are simply a function of enhanced numbers of live cells surviving due to PPBP. The present study cannot address no change in Bax RNA and protein concentration from our data. Unlike the in vivo literature, documented changes in bax as assessed in primary neuronal culture after "ischemia relevant" challenges are far from clear. In general, bcl-2 and bax have been less well studied in culture than in vivo. Furthermore, few investigations are available that evaluate bax mRNA or protein after OGD. More typical is the evaluation of serum deprivation, exposure to toxic apoptotic stimuli or exposure to oxidants or 3-NP. Others have reported no change in bax after these latter stimuli, e.g., after 3-nitropropionic acid challenge to rat cortical neurons (27) , and to serum deprivation in mouse neurons (28) .
Our data from primary cortical neurons agree with these studies in that postinsult bax mRNA levels as assessed by real-time PCR were not altered by PPBP. In contrast, studies that have used culture paradigms to follow bax translocation to the mitochondria during apoptosis have shown positive results, i.e., increases in bax in mitochondrial fraction. It may be that PPBP does alter translocation of bax, but our measurements do not allow us to comment on this possibility. Lastly, it is also possible that astrocytes provide a large amount of the bax signal when measurements are done in vivo. Others have shown that in vitro injury and ischemia alter bax levels in astrocytes, in a timedependent manner (29) .
In conclusion, these data obtained from in vitro cell injury models suggest novel downstream effects of PPBP application that are important to its neuroprotective properties. -receptor agonists such as PPBP have consistently shown efficacy across species and in varying animal models, perhaps due to multiple mechanisms involving presynaptic glutamate release and postsynaptic events, including expression of protective genes such as bcl-2.
